Should I buy or sell Certara stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Certara in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CERT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERT, but not buy additional shares or sell existing shares. View CERT analyst ratings or view top-rated stocks .

What is Certara's stock price target for 2024?

11 Wall Street research analysts have issued 1 year price objectives for Certara's shares. Their CERT share price targets range from $15.50 to $24.00. On average, they expect the company's share price to reach $20.06 in the next year. This suggests a possible upside of 25.9% from the stock's current price. View analysts price targets for CERT or view top-rated stocks among Wall Street analysts .

How have CERT shares performed in 2024?

Certara's stock was trading at $17.59 on January 1st, 2024. Since then, CERT stock has decreased by 9.4% and is now trading at $15.93. View the best growth stocks for 2024 here .

Are investors shorting Certara?

Certara saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 5,670,000 shares, an increase of 7.4% from the March 15th total of 5,280,000 shares. Based on an average trading volume of 550,800 shares, the days-to-cover ratio is currently 10.3 days. Currently, 5.2% of the company's shares are sold short. View Certara's Short Interest .

When is Certara's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our CERT earnings forecast .

How can I listen to Certara's earnings call?

Certara will be holding an earnings conference call on Tuesday, May 7th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link .

How were Certara's earnings last quarter?

Certara, Inc. (NASDAQ:CERT) released its earnings results on Thursday, February, 29th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.09 by $0.04. The firm earned $88.01 million during the quarter, compared to analyst estimates of $86.80 million. Certara had a positive trailing twelve-month return on equity of 4.33% and a negative net margin of 15.62%.

What ETFs hold Certara's stock?

ETFs with the largest weight of Certara (NASDAQ:CERT) stock in their portfolio include MFAM Small-Cap Growth ETF (MFMS) , Motley Fool Small-Cap Growth ETF (TMFS) , Invesco S&P SmallCap Health Care ETF (PSCH) , BlackRock Future Innovators ETF (BFTR) , Janus Henderson US Sustainable Equity ETF (SSPX) , Syntax Stratified SmallCap ETF (SSLY) and iShares U.S. Healthcare Providers ETF (IHF) . SPDR S&P 600 Small Cap ETF (SLY) .

What guidance has Certara issued on next quarter's earnings?

Certara issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of 0.410-0.460 for the period, compared to the consensus earnings per share estimate of 0.480. The company issued revenue guidance of $385.0 million-$400.0 million, compared to the consensus revenue estimate of $364.0 million.

When did Certara IPO?

Certara (CERT) raised $500 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 24,400,000 shares at $19.00-$22.00 per share. Jefferies, Morgan Stanley, BofA Securities, Credit Suisse, Barclays and William Blair acted as the underwriters for the IPO.

Who are Certara's major shareholders?

Certara's stock is owned by many different retail and institutional investors. Top institutional investors include Wasatch Advisors LP (3.07%), State of Alaska Department of Revenue (0.13%) and First Hawaiian Bank (0.02%). Insiders that own company stock include Avatar Parent LP Eqt, Craig R Rayner , Eran Broshy , James E Cashman III , Jieun W Choe , Justin Edge , Leif E Pedersen , Mason P Slaine , Matthew M Walsh , Michael Andrew Schemick , Patrick F Smith , Richard M Traynor , Robert Aspbury , Stephen M Mclean and William F Feehery . View institutional ownership trends .

How do I buy shares of Certara?

Shares of CERT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CERT

Certara (CERT) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free CERT Stock Alerts

$15.93

-0.28 (-1.73%)

(As of 04/19/2024 ET)

Compare

Today's Range: $15.83
▼
$16.32
50-Day Range: $15.93
▼
$19.45
52-Week Range: $11.81
▼
$24.96

Volume: 610,371 shs
Average Volume: 502,360 shs
Market Capitalization: $2.55 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $20.06

Get Certara alerts:

Certara MarketRank™ Stock Analysis

Analyst Rating: Hold
2.36 Rating Score
Upside/Downside: 25.9% Upside
$20.06 Price Target
Short Interest: Bearish
5.20% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.73
Upright™ Environmental Score
News Sentiment: 0.65
Based on 2 Articles This Week
Insider Trading: Selling Shares
$405,095 Sold Last Quarter
Proj. Earnings Growth: 20.69%
From $0.29 to $0.35 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.46 out of 5 stars

Medical Sector

109th out of 911 stocks

Prepackaged Software Industry

31st out of 196 stocks

4.2

Analyst's Opinion

Consensus Rating
Certara has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on 4 buy ratings, 7 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Certara has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
5.20% of the float of Certara has been sold short.
Short Interest Ratio / Days to Cover
Certara has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Certara has recently increased by 7.39%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Certara does not currently pay a dividend.
Dividend Growth
Certara does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Certara has received a 63.80% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Management consulting for the pharmaceutical industry", "Drug discovery software", and "Preclinical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Certara is -0.73.

2.6

News and Social Media Coverage

News Sentiment
Certara has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Certara this week, compared to 3 articles on an average week.
Search Interest
Only 3 people have searched for CERT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
8 people have added Certara to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Certara insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $405,095.00 in company stock.
Percentage Held by Insiders
Only 2.60% of the stock of Certara is held by insiders.
Percentage Held by Institutions
73.96% of the stock of Certara is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Certara are expected to grow by 20.69% in the coming year, from $0.29 to $0.35 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Certara is -45.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Certara is -45.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Certara has a PEG Ratio of 1.75. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Certara has a P/B Ratio of 2.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Certara Stock (NASDAQ:CERT)

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

CERT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CERT Stock News Headlines

April 5, 2024 | insidertrades.com

Insider Selling: Certara, Inc. (NASDAQ:CERT) Insider Sells 14,427 Shares of Stock

April 4, 2024 | insidertrades.com

Certara, Inc. (NASDAQ:CERT) SVP Sells $54,000.00 in Stock

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 16, 2024 | globenewswire.com

Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform

April 11, 2024 | americanbankingnews.com

Certara (NASDAQ:CERT) Upgraded at KeyCorp

April 9, 2024 | globenewswire.com

Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference

April 4, 2024 | finance.yahoo.com

Insider Sell: President of Drug Dev Solutions at Certara Inc (CERT) Sells Shares

April 4, 2024 | markets.businessinsider.com

Maintaining Hold Rating for Certara Amid Balanced Financials and Industry Headwinds

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 4, 2024 | markets.businessinsider.com

Decoding 4 Analyst Evaluations For Certara

April 1, 2024 | finance.yahoo.com

Certara, Inc.'s (NASDAQ:CERT) Intrinsic Value Is Potentially 66% Above Its Share Price

March 17, 2024 | finance.yahoo.com

CERT Apr 2024 22.500 call

March 14, 2024 | barrons.com

Schrodinger Inc.

March 3, 2024 | finance.yahoo.com

Certara Full Year 2023 Earnings: EPS Misses Expectations

March 2, 2024 | seekingalpha.com

Certara Inc. (CERT) Q4 2023 Earnings Call Transcript

March 2, 2024 | finance.yahoo.com

Certara, Inc. (NASDAQ:CERT) Q4 2023 Earnings Call Transcript

March 1, 2024 | ca.finance.yahoo.com

CERT Apr 2024 17.500 call

March 1, 2024 | finance.yahoo.com

Q4 2023 Certara Inc Earnings Call

February 29, 2024 | finance.yahoo.com

Certara Inc (CERT) Reports Modest Revenue Growth Amidst Net Loss in Q4 2023

February 29, 2024 | globenewswire.com

Certara Reports Fourth Quarter 2023 Financial Results

February 29, 2024 | msn.com

Stocks Slip Before the Open as Key U.S. Inflation Data Looms

February 26, 2024 | msn.com

Leerink Partners Initiates Coverage of Certara (CERT) with Market Perform Recommendation

February 23, 2024 | benzinga.com

Certara Stock (NASDAQ:CERT), Analyst Ratings, Price Targets, Predictions

February 21, 2024 | finance.yahoo.com

Is It Time To Consider Buying Certara, Inc. (NASDAQ:CERT)?

February 15, 2024 | finance.yahoo.com

Global Drug Discovery Informatics Market Report 2024-2028, 2033: Analysis by Service, Modality, Application, End-user and Region

February 8, 2024 | morningstar.com

Certara Inc Ordinary Shares CERT

February 1, 2024 | finance.yahoo.com

Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference

See More Headlines

Receive CERT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Certara and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/20/2024
Next Earnings (Confirmed): 5/07/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Prepackaged software
Sub-Industry: N/A
Current Symbol: NASDAQ:CERT
CUSIP: N/A
CIK: 1827090
Web: www.certara.com
Phone: 609-716-7900
Fax: N/A
Employees: 1,391
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $20.06
High Stock Price Target: $24.00
Low Stock Price Target: $15.50
Potential Upside/Downside: +25.9%
Consensus Rating: Hold
Rating Score (0-4): 2.36
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.35)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 54.93
P/E Growth: 1.75
Net Income: $-55,360,000.00
Net Margins: -15.62%
Pretax Margin: -15.56%
Return on Equity: 4.33%
Return on Assets: 2.98%

Debt

Debt-to-Equity Ratio: 0.28
Current Ratio: 2.62
Quick Ratio: 2.62

Sales & Book Value

Annual Sales: $354.34 million
Price / Sales: 7.20
Cash Flow: $0.89 per share
Price / Cash Flow: 17.91
Book Value: $6.55 per share
Price / Book: 2.43

Miscellaneous

Outstanding Shares: 160,190,000
Free Float: 156,026,000
Market Cap: $2.55 billion
Optionable: Optionable
Beta: 1.63

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. William F. Feehery Ph.D. (Age 53)
CEO & Director
Comp: $1.35M
Mr. Leif E. Pedersen (Age 59)
President & Chief Commercial Officer
Comp: $625.53k
Dr. Robert P. Aspbury Ph.D. (Age 52)
President of Certara Scientific Software
Comp: $518.09k
Dr. Patrick F. Smith Pharm.D. (Age 53)
President of Certara Drug Development Solutions
Comp: $621.58k
Mr. John E. Gallagher III (Age 51)
Chief Financial Officer
Mr. Max Kanevsky
Chief Technology Officer
Prof. Amin Rostami PharmD
Ph.D., FCP, Chief Scientific Officer
Mr. Richard M. Traynor (Age 52)
Senior VP, General Counsel & Secretary
Mr. Ron DiSantis
Senior Vice President of Corporate Development
Ms. Sheila Rocchio MBA
Chief Marketing Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CERT Stock Analysis - Frequently Asked Questions

Should I buy or sell Certara stock right now?: 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Certara in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CERT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERT, but not buy additional shares or sell existing shares.
View CERT analyst ratings or view top-rated stocks.
What is Certara's stock price target for 2024?: 11 Wall Street research analysts have issued 1 year price objectives for Certara's shares. Their CERT share price targets range from $15.50 to $24.00. On average, they expect the company's share price to reach $20.06 in the next year. This suggests a possible upside of 25.9% from the stock's current price.
View analysts price targets for CERT or view top-rated stocks among Wall Street analysts.
How have CERT shares performed in 2024?: Certara's stock was trading at $17.59 on January 1st, 2024. Since then, CERT stock has decreased by 9.4% and is now trading at $15.93.
View the best growth stocks for 2024 here.
Are investors shorting Certara?: Certara saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 5,670,000 shares, an increase of 7.4% from the March 15th total of 5,280,000 shares. Based on an average trading volume of 550,800 shares, the days-to-cover ratio is currently 10.3 days. Currently, 5.2% of the company's shares are sold short.
View Certara's Short Interest.
When is Certara's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our CERT earnings forecast.
How can I listen to Certara's earnings call?: Certara will be holding an earnings conference call on Tuesday, May 7th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Certara's earnings last quarter?: Certara, Inc. (NASDAQ:CERT) released its earnings results on Thursday, February, 29th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.09 by $0.04. The firm earned $88.01 million during the quarter, compared to analyst estimates of $86.80 million. Certara had a positive trailing twelve-month return on equity of 4.33% and a negative net margin of 15.62%.
What ETFs hold Certara's stock?: ETFs with the largest weight of Certara (NASDAQ:CERT) stock in their portfolio include MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), Invesco S&P SmallCap Health Care ETF (PSCH), BlackRock Future Innovators ETF (BFTR), Janus Henderson US Sustainable Equity ETF (SSPX), Syntax Stratified SmallCap ETF (SSLY) and iShares U.S. Healthcare Providers ETF (IHF).SPDR S&P 600 Small Cap ETF (SLY).
What guidance has Certara issued on next quarter's earnings?: Certara issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of 0.410-0.460 for the period, compared to the consensus earnings per share estimate of 0.480. The company issued revenue guidance of $385.0 million-$400.0 million, compared to the consensus revenue estimate of $364.0 million.
When did Certara IPO?: Certara (CERT) raised $500 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 24,400,000 shares at $19.00-$22.00 per share. Jefferies, Morgan Stanley, BofA Securities, Credit Suisse, Barclays and William Blair acted as the underwriters for the IPO.
Who are Certara's major shareholders?: Certara's stock is owned by many different retail and institutional investors. Top institutional investors include Wasatch Advisors LP (3.07%), State of Alaska Department of Revenue (0.13%) and First Hawaiian Bank (0.02%). Insiders that own company stock include Avatar Parent LP Eqt, Craig R Rayner, Eran Broshy, James E Cashman III, Jieun W Choe, Justin Edge, Leif E Pedersen, Mason P Slaine, Matthew M Walsh, Michael Andrew Schemick, Patrick F Smith, Richard M Traynor, Robert Aspbury, Stephen M Mclean and William F Feehery.
View institutional ownership trends.
How do I buy shares of Certara?: Shares of CERT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CERT) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial